Compare Lennar Corporation (LEN) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lennar Corporation vs TransMedics Group Inc — how do they compare? Lennar Corporation trades at $83.43 (market cap $19.92B), while TransMedics Group Inc trades at $73.86 (market cap $2.54B). The key difference: Lennar Corporation is far larger — about 7.8× TransMedics Group Inc's market cap, and Lennar Corporation pays a 2.41% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| LEN | TMDX | |
|---|---|---|
Market Cap | $19.92B | $2.54B |
Sector | Consumer Cyclical | Technology |
52-Week High | $142.40 | $150.42 |
52-Week Low | $82.30 | $61.99 |
Enterprise Value | $23.80B | $2.94B |
Dividend Yield | 2.41% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lennar (LEN) trades at $82.53, down 1.62% today, with a bearish technical signal and recent earnings misses. The stock shows attractive valuation metrics with a P/E of 13.15 and P/S of 0.64, but faces margin compression as net income fell to $2.08 billion in 2025. Recent news highlights housing affordability challenges and the company's strategy to prioritize volume over price, with average selling prices at 2017 levels (The Motley Fool, June 24, 2026).
The outlook is mixed: analyst consensus is a Buy with a $84.78 target, but technicals and earnings trends suggest near-term pressure. Key risks include rising mortgage rates and housing demand softness, while potential catalysts include margin recovery efforts and supportive housing legislation. Execution on cost discipline and market share gains will be critical for upside.
TransMedics (TMDX) trades at $73.47, down 0.69% with neutral technical signals. The stock shows strong profitability with 27% net margins and 45% ROE, though Q1 2026 earnings missed expectations. Recent strategic investment in European aviation logistics aims to expand the Organ Care System platform. Analyst consensus remains bullish with a $108.71 price target representing 48% upside potential.
Long-term growth prospects appear solid given TMDX's expanding transplant ecosystem, but near-term margin pressure from expansion investments and execution risks warrant caution. The company maintains competitive advantages in organ transplant logistics, though increased spending and competitive threats from alternatives like Strata Critical Medical present headwinds for shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
